20/20 BioLabs (NASDAQ: AIDX) cancer test sales surge 47% but losses widen
Rhea-AI Filing Summary
20/20 BioLabs, Inc. reported strong top-line improvement for the quarter ended June 30, 2026. Revenue rose 36.5% to $730,571 from $535,060, driven by OneTest™ multi-cancer early detection blood tests, which increased 47.1% to $697,034 and represented 95.3% of total revenue.
Gross profit grew 86.6% to $304,727, with gross margin expanding to 41.7% from 30.5%, reflecting favorable mix and better fixed-cost absorption. However, operating expenses increased to $1.55 million from $1.01 million, largely due to Nasdaq listing costs and product development spend, leading to a quarterly net loss of $1.51 million versus $0.84 million a year earlier.
For the first half of 2026, revenue was essentially flat at $1.08 million, while net loss widened to $3.68 million. Liquidity improved meaningfully: cash rose to $4.55 million at June 30, 2026 from $1.03 million at year-end 2025, primarily from $6.0 million of Series E preferred financing, and all convertible note debt was eliminated. Stockholders’ equity turned positive at $1.62 million from a slight deficit.
Positive
- Q2 2026 revenue grew 36.5% to $730,571, led by OneTest™ cancer testing, which increased 47.1% and made up over 95% of total revenue.
- Gross margin expanded to 41.7% from 30.5% year over year in Q2 2026, with gross profit up 86.6% to $304,727, indicating improved unit economics.
- Cash and cash equivalents increased to $4.55 million at June 30, 2026 from $1.03 million at year-end 2025, supported by $6.0 million of Series E preferred financing.
- All convertible note debt was eliminated by June 30, 2026, simplifying the capital structure and reducing future interest obligations.
- Stockholders’ equity improved to a positive $1.62 million at June 30, 2026 from a small deficit of $19,225 at December 31, 2025.
Negative
- Net loss widened to $1.51 million in Q2 2026 from $0.84 million in Q2 2025, with first-half 2026 net loss more than doubling to $3.68 million.
- Operating expenses rose to $1.55 million in Q2 2026 from $1.01 million a year earlier and to $3.06 million for the first half, reflecting higher public-company and development costs.
- Net loss attributable to common stockholders increased to $2.75 million in Q2 2026 from $0.84 million, impacted by a $1.12 million deemed dividend on warrant modifications and preferred dividends.
- First-half 2026 revenue was flat at $1.08 million versus $1.09 million in the prior-year period, indicating growth was concentrated in the second quarter.
Filing Explained
As of June 30, 2026, common shares were 12,251,198 and Series E preferred stock carried a $6,273,600 liquidation preference.
This Form 8-K furnishes 20/20 BioLabs’ second-quarter results for the period ended
That higher common share count reduces an existing holder’s percentage ownership absent offsetting changes. The company also reported 5,228 Series E convertible preferred shares outstanding, presented as contingently redeemable preferred stock with a
At June 30, cash was
8-K Event Classification
Key Figures
Key Terms
multi-cancer early detection medical
MCED medical
contingently redeemable convertible preferred stock financial
derivative liabilities financial
deemed dividend financial
Clinical Laboratory Improvement Amendments medical
Offering Details
FAQ
How did 20/20 BioLabs (AIDX) perform financially in Q2 2026?
What drove revenue growth for 20/20 BioLabs (AIDX) in Q2 2026?
How did 20/20 BioLabs’ (AIDX) profitability metrics change in Q2 2026?
What is 20/20 BioLabs’ (AIDX) cash position and debt status as of June 30, 2026?
How did first-half 2026 results for 20/20 BioLabs (AIDX) compare to 2025?
What capital transactions affected 20/20 BioLabs (AIDX) in the first half of 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Exact name of registrant as specified in its charter) |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
| (Registrant’s telephone number, including area code) |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging Growth Company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 17, 2026, 20/20 Biolabs, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release issued on August 17, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 17, 2026 | 20/20 BIOLABS, INC. | |
| /s/ Jonathan Cohen | ||
| Name: | Jonathan Cohen | |
| Title: | Chief Executive Officer | |
2
Exhibit 99.1
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
Total Revenue Increased 37% to $0.7 Million and Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5%
Best Quarter of Multi-Cancer Early Detection Testing, with OneTest™ Revenue Up 47% Year-Over-Year to $0.7 Million
Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter
Gaithersburg, MD - August 17, 2026 - 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the second quarter ended June 30, 2026.
Second Quarter & Subsequent 2026 Operational Highlights
| ● | Total revenue increased 36.5% to $0.7 million for Q2 2026, as compared to $0.5 million for Q2 2025, with OneTest™ accounting for 95.3% of total revenue in the quarter, up from 88.4% in the prior year period. |
| ● | Revenue from the Company’s OneTest™ family of blood tests, led by OneTest™ for Cancer, its Multi-Cancer Early Detection (“MCED”) blood test, increased 47.1% to $0.7 million for Q2 2026, as compared to $0.5 million for Q2 2025. The Company believes Q2 2026 represented its strongest quarter of MCED testing. |
| ● | Gross profit increased 86.6% to $0.3 million for Q2 2026, as compared to $0.2 million for Q2 2025, while gross margin expanded to 41.7% from 30.5%, reflecting improved absorption of fixed laboratory costs across a higher volume of OneTest™ tests. |
| ● | State-funded firefighter cancer screening programs continued to gain momentum. In May, the State of Vermont selected OneTest™ for a 12-month statewide initiative to screen up to 4,500 firefighters, while Maryland fire departments were awarded $520,000 for OneTest™ cancer screenings. The Company expects these programs to generate more than $1.0 million of revenue through the end of 2026. |
| ● | The Company expects to have tested more than 35,000 firefighters by the end of 2026, building a body of real-world evidence intended to support its regulatory and reimbursement strategy. |
| ● | Received orders from 29 new accounts during the second quarter, including occupational and preventive health companies, fire departments and primary care physician practices. Growth has continued into the third quarter across fire department, occupational health, military service and physician practice markets. |
| ● | Executed a purchase agreement with the TF – 7294 Foundation that expands access to OneTest™ for Cancer within the U.S. Intelligence Community. |
| ● | Received a first commercial order from BodyMetRX, extending the OneTest™ for Cancer footprint into the health optimization and wellness market. |
| ● | Maintained strong repeat business from existing customers, with Clayton County, Georgia beginning its seventh year of OneTest™ for Cancer screening, and continued to grow its enterprise pipeline entering the second half of 2026. |
| ● | Launched a three-month retail pilot with Giant Food for OneTest for Longevity™, making the Company’s inflammatory and cardiometabolic biomarker testing available through participating Giant Food stores via pharmacy-based blood collection and at-home self-collection kits. |
| ● | Cash and cash equivalents totaled $4.5 million as of June 30, 2026, compared to $1.0 million as of December 31, 2025. |
| ● | Issued an additional 1,000 shares of Series E convertible preferred stock on June 16, 2026 for gross proceeds of $1.0 million, bringing total Series E proceeds to $6.0 million for the first half of 2026 under a preferred purchase agreement pursuant to which up to $40.0 million in capital may be raised in multiple tranches, subject to 20/20 meeting certain conditions. |
| ● | Subsequent to the first quarter, on April 10, 2026, all principal and accrued interest outstanding under the Company’s secured convertible promissory notes was exchanged for 583 shares of Series E convertible preferred stock, eliminating all convertible note debt from the Company’s balance sheet as of June 30, 2026. |
| ● | Subsequent to quarter end, on July 16, 2026, the Company entered into a standstill agreement with Streeterville under which Streeterville agreed that, for 120 days, it will not convert shares of Series E convertible preferred stock into common stock unless the common stock trades at least 10% above the “Minimum Price” as defined in Nasdaq Rule 5635. |
| ● | Accounts receivable increased to approximately $0.3 million as of June 30, 2026, compared to $0.2 million as of December 31, 2025, reflecting higher MCED testing volume late in the quarter. |
| ● | Hosted the inaugural session of a new monthly investor webinar series on July 1, 2026, focused on the Company’s Medicare strategy for OneTest™ and its serial biomarker tracking methodology. Sessions are held on the first Wednesday of each month. |
| ● | Continued to advance the Company’s patented protein tumor marker based, machine learning derived MCED methodology, which tracks biomarker trajectories over time rather than relying on single-point testing, an approach the Company believes may support earlier-stage detection compared to stand-alone circulating tumor DNA based MCEDs. |
Management Commentary
Chief Executive Officer Jonathan Cohen commented, “The second quarter was the strongest quarter of multi-cancer early detection testing this Company has ever delivered. OneTest™ revenue grew 47% year-over-year to $0.7 million and represented more than 95% of total revenue, which is exactly the mix shift we have been working toward. Just as importantly, that growth came with operating leverage: gross profit increased 87% and gross margin expanded more than 11 percentage points to 41.7%, because our laboratory absorbs incremental testing volume at attractive incremental economics.”
“State-funded firefighter cancer screening continues to validate OneTest™ in a meaningful commercial setting. Programs in Maryland and Vermont are expected to help us surpass 35,000 firefighters tested by year-end, generating valuable real-world evidence while contributing to revenue growth.”
2
“That growing body of clinical data supports our long-term reimbursement strategy. With a statutory Medicare pathway for FDA-authorized MCED blood tests beginning in 2028, we believe OneTest™ is well positioned to benefit from expanding adoption as we continue advancing toward commercialization.”
Chief Financial Officer Alan Bergman added, “Second quarter results reflected a return to growth, with revenue increasing 36.5% year over year and gross profit increasing 87% as higher OneTest™ volume drove meaningful operating leverage. Operating expenses increased primarily due to one-time Nasdaq listing costs and continued investment in our longevity platform.
“We also strengthened the balance sheet meaningfully. During the quarter, we strengthened the balance sheet by raising additional Series E preferred capital and eliminating all outstanding convertible note debt. We ended the quarter with $4.5 million in cash and believe we are well positioned to support continued growth in MCED testing. With two state firefighter programs now contributing and a growing commercial pipeline, we expect MCED volume to remain the primary driver of revenue growth through the balance of the year,” concluded Bergman.
Second Quarter 2026 Financial Results
Total revenue for the three months ended June 30, 2026 was $0.7 million, an increase of 36.5%, compared to $0.5 million in the prior year period. Revenue from OneTest™, which includes the Company’s MCED blood test, increased 47.1% to $0.7 million, compared to $0.5 million in the prior year period, and represented 95.3% of total revenue, compared to 88.4% in the prior year period.
Total cost of revenue for the three months ended June 30, 2026 was $0.4 million, compared to $0.4 million in the prior year period.
Gross profit for the three months ended June 30, 2026 was $0.3 million, an increase of 86.6%, compared to $0.2 million in the prior year period. Gross margin was 41.7% in Q2 2026, compared to 30.5% in the prior year period, reflecting favorable product mix and improved fixed-cost absorption.
Operating expenses increased to $1.5 million from $1.0 million, primarily reflecting expenses associated with the Company’s Nasdaq direct listing and continued investment in product development.
Total other expense, net was $0.3 million for the three months ended June 30, 2026, compared to other income, net, of less than $0.1 million in the prior year period.
Net loss for the three months ended June 30, 2026 was $1.5 million, compared to $0.8 million in the prior year period. Net loss included approximately $0.7 million in non-cash charges.
Cash and cash equivalents totaled $4.5 million as of June 30, 2026, compared to $1.0 million at year-end 2025, primarily reflecting $6.0 million of Series E preferred financing completed during the first half of the year. The Company had no convertible note debt outstanding at quarter end.
3
First Half 2026 Financial Results
Total revenue for the six months ended June 30, 2026 was $1.1 million, compared to $1.1 million in the prior year period. Revenue from OneTest™ increased 6.5% to $1.0 million, compared to $0.9 million in the prior year period.
Gross profit for the six months ended June 30, 2026 was $0.4 million, an increase of 11.7%, compared to $0.3 million in the prior year period. Gross margin was 33.9%, compared to 30.2% in the prior year period.
Total operating expenses for the six months ended June 30, 2026 were $3.1 million, compared to $1.9 million in the prior year period, primarily reflecting expenses associated with the Company’s transition to a Nasdaq-listed public company.
Net loss for the six months ended June 30, 2026 was $3.7 million, compared to $1.6 million in the prior year period. Net loss included approximately $1.7 million in non-cash charges.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper-arm capillary collection devices that avoid painful needles. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com.
Forward-Looking Statements
Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions. Actual results may differ materially from those expressed or implied by such forward-looking statements, including, without limitation, statements regarding expected revenue from state-funded firefighter cancer screening programs, the number of firefighters expected to be tested, the Giant Food retail pilot and whether it results in business beyond the pilot term, the Company’s expectations regarding new customer orders and its commercial pipeline, the Company’s ability to obtain FDA authorization for OneTest™ for Cancer or Medicare coverage or reimbursement, and the Company’s expectations regarding future revenue growth and liquidity. A number of factors could cause actual results to differ materially from those contained in these forward-looking statements, including, but not limited to, the risks described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K, as well as in our other reports filed or furnished from time to time with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law. Although the Company believes the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee future results, and investors are cautioned that actual outcomes may differ materially from those anticipated.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
4
20/20 BIOLABS, INC.
CONDENSED BALANCE SHEETS
(UNAUDITED)
June 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 4,546,140 | $ | 1,025,987 | ||||
| Accounts receivable, net | 291,486 | 199,954 | ||||||
| Inventory | 111,036 | 116,217 | ||||||
| Prepaid expenses and other current assets | 126,961 | 128,975 | ||||||
| Total current assets | 5,075,623 | 1,471,133 | ||||||
| License agreement, net | 265,518 | 271,143 | ||||||
| Property and equipment, net | 33,700 | 56,677 | ||||||
| Intangible asset, net | 205,985 | 202,264 | ||||||
| Right-of-use assets, net | 519,302 | 605,289 | ||||||
| Deferred financing costs | - | 1,507,794 | ||||||
| Other assets | 23,057 | 23,057 | ||||||
| Total assets | $ | 6,123,185 | $ | 4,137,357 | ||||
| Liabilities and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,026,809 | $ | 868,545 | ||||
| Accrued liabilities | 743,001 | 785,784 | ||||||
| Accrued dividends – Series E convertible preferred stock | 121,662 | - | ||||||
| Deferred revenue – current | 467,033 | 414,871 | ||||||
| Derivative liability – current | - | 143,382 | ||||||
| Convertible notes payable – current | - | 74,611 | ||||||
| Operating lease liability – current | 192,731 | 175,948 | ||||||
| Total current liabilities | 2,551,236 | 2,463,141 | ||||||
| Long-term liabilities: | ||||||||
| Convertible notes payable, net | - | 619,355 | ||||||
| Deferred revenue – long-term | 32,924 | 41,816 | ||||||
| Derivative liabilities – long-term | - | 543,545 | ||||||
| Operating lease liability – long term | 379,717 | 488,725 | ||||||
| Total long-term liabilities | 412,641 | 1,693,441 | ||||||
| Total liabilities | 2,963,877 | 4,156,582 | ||||||
| Commitments and contingencies (Note 9) | - | - | ||||||
| Contingently redeemable convertible preferred stock: | ||||||||
| Series E convertible preferred stock, $0.01 par value; 45,000 authorized; 5,228 and 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; liquidation preference of $6,273,600 | 1,538,608 | - | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Series D preferred stock, $0.01 par value; 936,329 authorized; 0 and 101,565 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | - | 1,016 | ||||||
| Series C preferred stock, $0.01 par value; 3,340,909 authorized; 0 and 1,204,040 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | - | 12,040 | ||||||
| Series B preferred stock, $0.01 par value; 3,569,405 authorized; 0 and 1,471,487 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | - | 14,715 | ||||||
| Series A-2 preferred stock, $0.01 par value; 800,000 authorized; 0 and 442,402 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | - | 4,424 | ||||||
| Series A-1 preferred stock, $0.01 par value; 978,000 authorized; 0 and 651,465 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | - | 6,515 | ||||||
| Series A preferred stock, $0.01 par value; 1,303,000 authorized; 0 and 846,368 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | - | 8,464 | ||||||
| Common stock, $0.01 par value; 50,000,000 authorized; 12,251,198 and 5,442,249 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 122,512 | 54,422 | ||||||
| Additional paid-in capital | 38,426,586 | 33,126,398 | ||||||
| Accumulated deficit | (36,928,398 | ) | (33,247,219 | |||||
| Total stockholders’ equity (deficit) | 1,620,700 | (19,225 | ||||||
| Total liabilities, contingently redeemable preferred stock and stockholders’ equity (deficit) | $ | 6,123,185 | $ | 4,137,357 | ||||
5
20/20 BIOLABS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | $ | 730,571 | $ | 535,060 | $ | 1,083,946 | $ | 1,088,880 | ||||||||
| Cost of revenues | 425,844 | 371,796 | 716,335 | 759,822 | ||||||||||||
| Gross profit | 304,727 | 163,264 | 367,611 | 329,058 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales, general and administrative | 1,291,318 | 814,811 | 2,644,076 | 1,615,955 | ||||||||||||
| Research and development | 257,632 | 194,124 | 411,114 | 330,955 | ||||||||||||
| Total operating expenses | 1,548,950 | 1,008,935 | 3,055,190 | 1,946,910 | ||||||||||||
| Operating loss | (1,244,223 | ) | (845,671 | ) | (2,687,579 | ) | (1,617,852 | |||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | (272,245 | ) | (935 | ) | (539,254 | ) | (1,675 | |||||||||
| Interest income | 14,476 | 5,673 | 21,129 | 14,131 | ||||||||||||
| Loss on change in fair value of warrant liability | - | - | (148,766 | ) | - | |||||||||||
| Loss on issuance of convertible note | (4,236 | ) | - | (326,595 | ) | - | ||||||||||
| Other expense, net | (115 | ) | - | (115 | ) | (115 | ||||||||||
| Total other (expense) income | (262,120 | ) | 4,738 | (993,601 | ) | 12,341 | ||||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | (1,506,343 | ) | (840,933 | ) | (3,681,180 | ) | (1,605,511 | |||||||||
| Deemed dividend on warrant modifications | (1,124,676 | ) | - | (1,124,676 | ) | - | ||||||||||
| Preferred stock dividends | (121,662 | ) | - | (175,854 | ) | - | ||||||||||
| Net loss attributable to common stockholders | $ | (2,752,681 | ) | $ | (840,933 | ) | $ | (4,981,710 | ) | $ | (1,605,511 | |||||
| Basic and diluted net loss per common share | $ | (0.26 | ) | $ | (0.17 | ) | $ | (0.54 | ) | $ | (0.33 | |||||
| Weighted-average common shares outstanding, basic and diluted | 10,790,722 | 4,823,125 | 9,230,710 | 4,823,125 | ||||||||||||
6
20/20 BIOLABS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| Six Months Ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (3,681,180 | ) | $ | (1,605,511 | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 24,610 | 33,304 | ||||||
| Stock based compensation | 499,740 | 259,300 | ||||||
| Amortization of license fees | 13,125 | 11,250 | ||||||
| Issuance of common stock for services | 181,500 | - | ||||||
| Loss on issuance of convertible note | 322,359 | - | ||||||
| Amortization of right-of-use assets, net of liabilities | (6,238 | ) | (3,676 | |||||
| Amortization of debt discount | 515,583 | - | ||||||
| Change in fair value of derivative liability | 148,766 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (91,532 | ) | (38,979 | |||||
| Inventory | 5,181 | (14,496 | ||||||
| Prepaid expenses and other assets | 2,014 | 53,770 | ||||||
| Accounts payable | 158,265 | 184,333 | ||||||
| Accrued liabilities | (29,883 | ) | 192,468 | |||||
| Deferred revenue | 43,270 | (94,161 | ||||||
| Net cash used in operating activities | (1,894,420 | ) | (1,022,398 | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of intangible assets, including patents | (5,354 | ) | - | |||||
| License agreement | (7,500 | ) | - | |||||
| Net cash used in investing activities | (12,854 | ) | - | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of convertible notes payable | 250,000 | 70,000 | ||||||
| Proceeds from issuance of series D preferred stock | - | 192,338 | ||||||
| Proceeds from issuance of series E convertible preferred stock | 6,000,000 | - | ||||||
| Offering costs | (822,573 | ) | - | |||||
| Net cash provided by financing activities | 5,427,427 | 262,338 | ||||||
| Increase (decrease) in cash and cash equivalents | 3,520,153 | (760,060 | ||||||
| Cash and cash equivalents, beginning of period | 1,025,987 | 1,784,009 | ||||||
| Cash and cash equivalents, end of period | $ | 4,546,140 | $ | 1,023,949 | ||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | - | $ | - | ||||
| Cash paid for income taxes | $ | - | $ | - | ||||
| Non-cash disclosures of cash flow information: | ||||||||
| Conversion of preferred stock to common stock | $ | 289,193 | $ | - | ||||
| Deferred offering costs – issuance of common stock and warrants as offering costs | $ | 3,654,057 | $ | - | ||||
| Accrued dividends on series E convertible preferred stock | $ | 121,662 | $ | - | ||||
| Deemed dividend on warrant modifications | $ | 1,124,676 | $ | - | ||||
| Issuance of preferred stock for dividends on series E convertible preferred stock | $ | 54,192 | $ | - | ||||
| Derivative liabilities recognized as debt discounts | $ | 541,199 | $ | - | ||||
| Derivative liabilities reclassified to equity | $ | 1,361,306 | $ | - | ||||
| Conversion of convertible notes payable and accrued interest to common stock | $ | 834,812 | $ | - | ||||
| Conversion of convertible notes payable and accrued interest to Series E Preferred | $ | 583,197 | $ | - | ||||
7